- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07581470
Intravenous Dexamethasone (0 vs 4 vs 8 mg) as an Adjunct to PENG Block for Postoperative Analgesia in Total Hip Arthroplasty
Trial Evaluating Intravenous Dexamethasone (0 vs 4 vs 8 mg) as an Adjunct to PENG Block for Postoperative Analgesia in Total Hip Arthroplasty
his study will test whether giving dexamethasone through a vein can improve pain control after total hip replacement surgery. Dexamethasone is commonly used to reduce nausea and may also help with pain, but it is not clear which dose works best. Patients will be randomly assigned to receive either no dexamethasone, 4 mg, or 8 mg, in addition to standard anesthesia and a nerve block (PENG block). The main goal is to see how long patients go without needing additional pain medication after surgery. The study will also look at pain levels, use of opioid painkillers, nausea and vomiting, blood sugar levels, and possible side effects.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Effective pain control after total hip arthroplasty (THA) remains a key component of perioperative care, as inadequate analgesia may delay mobilization, prolong hospital stay, and increase the need for opioids. Regional anesthesia techniques, such as the pericapsular nerve group (PENG) block, are increasingly used to improve postoperative pain management while preserving motor function.
Dexamethasone administered intravenously is commonly used in perioperative care, primarily for the prevention of postoperative nausea and vomiting. In addition, it has been shown to prolong the duration of analgesia when used as an adjunct to regional anesthesia. However, there is still uncertainty regarding the optimal intravenous dose that provides clinically meaningful analgesic benefit without increasing the risk of adverse effects, particularly hyperglycemia.
Previous studies have typically used doses ranging from 4 mg to 8 mg, but direct comparisons between these doses, as well as comparison with placebo, remain limited in patients undergoing THA. Furthermore, the potential dose-response relationship of intravenous dexamethasone in this specific surgical population has not been clearly established.
This study is designed to address this knowledge gap by evaluating whether intravenous dexamethasone provides additional analgesic benefit in patients undergoing THA with PENG block, and whether higher doses result in improved outcomes compared to lower doses or no dexamethasone. The findings may help optimize perioperative analgesic strategies and support more evidence-based dosing of dexamethasone in orthopedic surgery.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Małgorzata Reysner, MD PhD
- Numero di telefono: +48 (61) 8310122
- Email: mreysner@ump.edu.pl
Backup dei contatti dello studio
- Nome: Tomasz Reysner, MD PhD
- Numero di telefono: +48 (61) 8310122
- Email: mreysner@ump.edu.pl
Luoghi di studio
-
-
-
Poznan, Polonia, 62-701
- Reclutamento
- Poznan University of Medical Sciences
-
Contatto:
- Malgorzata Reysner, M.D. Ph.D.
- Numero di telefono: +48 61 873 83 03
- Email: mreysner@ump.edu.pl
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Age ≥ 18 years
- Scheduled for elective total hip arthroplasty (THA)
- Planned use of regional anesthesia including PENG block
- American Society of Anesthesiologists (ASA) physical status I-III
- Ability to understand the study procedures and provide written informed consent
- Ability to assess pain using the Numeric Rating Scale (NRS)
Exclusion Criteria:
- Known hypersensitivity to dexamethasone or any component of the study medication
- Chronic corticosteroid therapy or use of systemic steroids within 14 days prior to surgery
- Active systemic infection or sepsis
- Significant immunosuppression (e.g., chemotherapy, biological therapy)
- Pregnancy or breastfeeding
- Severe cognitive impairment or inability to reliably assess pain
- Uncontrolled diabetes mellitus (e.g., HbA1c > 8.5% or baseline blood glucose > 200 mg/dL)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore placebo: Placebo (0 mg Intravenous Dexamethasone)
Participants receive placebo (0.9% sodium chloride) administered intravenously in a volume identical to active treatment after induction of anesthesia. All patients receive standard anesthesia, multimodal analgesia, and an ultrasound-guided PENG block with 20 mL of 0.2% ropivacaine. |
Intravenous administration of 0.9% sodium chloride in a volume identical to active treatment, given after induction of anesthesia.
Altri nomi:
|
|
Comparatore attivo: Dexamethasone 4 mg Intravenous
Participants receive 4 mg dexamethasone administered intravenously after induction of anesthesia. All patients receive standard anesthesia, multimodal analgesia, and an ultrasound-guided PENG block with 20 mL of 0.2% ropivacaine. |
Intravenous dexamethasone administered as a single dose after induction of anesthesia, at doses of 4 mg
Altri nomi:
|
|
Comparatore attivo: Dexamethasone 8 mg Intravenous
Participants receive 8 mg dexamethasone administered intravenously after induction of anesthesia. All patients receive standard anesthesia, multimodal analgesia, and an ultrasound-guided PENG block with 20 mL of 0.2% ropivacaine. |
Intravenous dexamethasone administered as a single dose after induction of anesthesia, at doses of 8 mg
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Time to First Rescue Analgesia
Lasso di tempo: 48 hours after surgery
|
Time from the end of surgery to the first administration of rescue analgesia (opioid) due to inadequate pain control (Numeric Rating Scale ≥ 4 or patient request). |
48 hours after surgery
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Postoperative Pain Intensity
Lasso di tempo: 6 hours after surgery
|
Pain intensity at rest assessed using an 11-point Numeric Rating Scale (NRS, 0 = no pain, 10 = worst imaginable pain) |
6 hours after surgery
|
|
Postoperative Pain Intensity
Lasso di tempo: 12 hours after surgery
|
Pain intensity at rest assessed using an 11-point Numeric Rating Scale (NRS, 0 = no pain, 10 = worst imaginable pain) |
12 hours after surgery
|
|
Postoperative Pain Intensity
Lasso di tempo: 24 hours after surgery
|
Pain intensity at rest assessed using an 11-point Numeric Rating Scale (NRS, 0 = no pain, 10 = worst imaginable pain) |
24 hours after surgery
|
|
Postoperative Pain Intensity
Lasso di tempo: 48 hours after surgery
|
Pain intensity at rest assessed using an 11-point Numeric Rating Scale (NRS, 0 = no pain, 10 = worst imaginable pain) |
48 hours after surgery
|
|
Opioid Consumption
Lasso di tempo: 48 hours after surgery
|
Total opioid consumption converted to morphine milligram equivalents (MME). |
48 hours after surgery
|
|
Opioid Consumption
Lasso di tempo: 24 hours after surgery
|
Total opioid consumption converted to morphine milligram equivalents (MME). |
24 hours after surgery
|
|
Incidence of Postoperative Nausea and Vomiting (PONV)
Lasso di tempo: 24 hours after surgery
|
Occurrence of nausea and/or vomiting and need for antiemetic treatment. |
24 hours after surgery
|
|
Blood Glucose Levels
Lasso di tempo: immidietly after surgery (0 hours after surgery)
|
Perioperative blood glucose measurements to assess the metabolic effect of dexamethasone. |
immidietly after surgery (0 hours after surgery)
|
|
Blood Glucose Levels
Lasso di tempo: 6 hours after surgery
|
Perioperative blood glucose measurements to assess the metabolic effect of dexamethasone. |
6 hours after surgery
|
|
Blood Glucose Levels
Lasso di tempo: 12 hours after surgery
|
Perioperative blood glucose measurements to assess the metabolic effect of dexamethasone. |
12 hours after surgery
|
|
Blood Glucose Levels
Lasso di tempo: 24 hours after surgery
|
Perioperative blood glucose measurements to assess the metabolic effect of dexamethasone. |
24 hours after surgery
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Justyna Marszałek-Buko, MD, Poznan University of Medical Sciences
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie muscoloscheletriche
- Artrite
- Malattie articolari
- Malattie reumatiche
- Osteoartrite
- Osteoartrite, anca
- Composti policiclici
- Prodotti chimici inorganici
- Composti di cloro
- Incinta
- In gravidanza
- Steroidi
- Composti anelli fusi
- Steroidi, fluorurati
- Incintadienetrioli
- Composti di sodio
- Cloruri
- Acido cloridrico
- Desametasone
- desametasone 21-fosfato
- Cloruro di sodio
Altri numeri di identificazione dello studio
- 3/2026
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .